Kennedy Kelly J. 4

What Happened
Kelly J. Kennedy, a director of GoodRx Holdings, received an award of 73,434 restricted stock units (RSUs) on 2026-06-16. The Form 4 reports the acquisition price as $0.00 (code A — award/grant). The filing does not report a cash value; the economic value will equal the market price of GoodRx shares at the time the RSUs vest and convert into shares.

Key Details

• Transaction date: 2026-06-16; Filing date (accession): 2026-06-17 (timely filing).
• Transaction type/code: Award/Grant (A). Reported acquisition price: $0.00.
• Number of RSUs: 73,434. Each RSU represents a contingent right to one share of Class A common stock (see footnote).
• Vesting: RSUs vest in full on the earlier of (i) the one-year anniversary of June 16, 2026 or (ii) the date of the 2027 Annual Meeting of Stockholders, subject to continued service.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote highlights: These are restricted stock units (F1) — not an open-market purchase; they are compensation-related and subject to vesting and continued service requirements.

Context
RSU grants are a common form of equity compensation for executives and directors. They do not require an upfront cash purchase and do not immediately increase tradable share count until the units vest and convert to shares. This award should be viewed as a compensation event rather than a direct bullish purchase signal.